Martin-Varillas, J. L.Sanchez-Bilbao, L.Calvo-Rio, V.Adan, A.Hernanz Rodriguez, I.Beltran, E.Castro, S.Fanlo Mateo, P.Garcia Martos, A.Torre-Salaberri, I.Cordero-Coma, M.De Dios-Jimenez Aberasturi, J.Garcia-Aparicio, A.Hernandez-Garfella, M.Sanchez-Andrade, A.Garcia-Valle, A.Miguelez, R.Maiz, O.Rodriguez Montero, S.Urruticoechea-Arana, A.Veroz Gonzalez, R.Conesa, A.Fernandez-Carballido, C.Jovani, V.Martinez Gonzalez, O.Moya, P.Romero-Yuste, S.Rubio Munoz, P.Pena Sainz-Pardo, E.Garijo Bufort, M.Hernandez, J. L.Blanco, R.2023-05-032023-05-032022-06-010003-4967http://hdl.handle.net/10668/20092enAdalimumabUVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTICENTER STUDY OF 80 PATIENTS.conference outputopen access10.1136/annrheumdis-2022-eular.30491468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/1013.2.full.pdf850279004070